PEGPH20
HALO-107-101
Phase 1 small_molecule completed
Quick answer
PEGPH20 for NSCLC is a Phase 1 program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- HALOZYME THERAPEUTICS, INC.
- Indication
- NSCLC
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed